• Millendo May Restructure After Prader-Willi Drug Fails Pivotal Test

    1 month ago - By Xconomy

    Millendo Therapeutics is considering a corporate reorganization after its lead drug, an investigational treatment for a rare genetic condition characterized by unrelenting hunger, did not perform better than a placebo in a pivotal trial. The Ann Arbor, MI-based company said Monday that the drug, livoletide, did not meet the goal of the Phase 2b study evaluating it as a treatment for Prader-Willi syndrome. People with this condition -the most common genetic cause of life-threatening childhood obesity-have an insatiable appetite that leads to chronic overeating, or hyperphagia. Millendo...
    Read more ...